Risk of venous thromboembolism amongst initiators of SGLT-2 inhibitors compared to other glucose-lowering agents

被引：0
|
作者：
Gopalakrishnan, Chandrasekar [1 ]
Desai, Rishi J. [1 ]
Kim, Seoyoung C. [1 ]
Patorno, Elisabetta [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3982
引用
收藏
页码：591 / 592
页数：2
相关论文
共 50 条
  • [41] Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
    Nagasu, Hajime
    Yano, Yuichiro
    Kanegae, Hiroshi
    Heerspink, Hiddo J. L.
    Nangaku, Masaomi
    Hirakawa, Yosuke
    Sugawara, Yuka
    Nakagawa, Naoki
    Tani, Yuji
    Wada, Jun
    Sugiyama, Hitoshi
    Tsuruya, Kazuhiko
    Nakano, Toshiaki
    Maruyama, Shoichi
    Wada, Takashi
    Yamagata, Kunihiro
    Narita, Ichiei
    Tamura, Kouichi
    Yanagita, Motoko
    Terada, Yoshio
    Shigematsu, Takashi
    Sofue, Tadashi
    Ito, Takafumi
    Okada, Hirokazu
    Nakashima, Naoki
    Kataoka, Hiromi
    Ohe, Kazuhiko
    Okada, Mihoko
    Itano, Seiji
    Nishiyama, Akira
    Kanda, Eiichiro
    Ueki, Kohjiro
    Kashihara, Naoki
    DIABETES CARE, 2021, 44 (11) : 2542 - 2551
  • [42] Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
    Liakos, Charalampos I.
    Papadopoulos, Dimitrios P.
    Sanidas, Elias A.
    Markou, Maria I.
    Hatziagelaki, Erifili E.
    Grassos, Charalampos A.
    Velliou, Maria L.
    Barbetseas, John D.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (02) : 123 - 137
  • [43] Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
    Kosiborod, Mikhail
    Birkeland, Kare I.
    Cavender, Matthew A.
    Fu, Alex Z.
    Wilding, John P.
    Khunti, Kamlesh
    Holl, Reinhard W.
    Norhammar, Anna
    Jorgensen, Marit E.
    Wittbrodt, Eric T.
    Thuresson, Marcus
    Bodegard, Johan
    Hammar, Niklas
    Fenici, Peter
    DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1983 - 1987
  • [44] Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
    Neumiller, Joshua J.
    Herrin, Jeph
    Swarna, Kavya
    Polley, Eric
    Galindo, Rodolfo J.
    Umpierrez, Guillermo
    Deng, Yihong
    Mickelson, Mindy
    McCoy, Rozalina G.
    DIABETES, 2024, 73
  • [45] Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus - New Findings on SGLT2 Inhibitors
    Brinkmann, Christian
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [46] Effectiveness of SodiumGlucose Cotransporter 2 Inhibitors on Coronary Heart Disease Compared with Other Glucose Lowering Drugs
    Shen, Yun
    Zhou, Jian
    Shi, Lizheng
    Nauman, Elizabeth
    Katzmarzyk, Peter T.
    Price-Haywood, Eboni G.
    Chu, San
    Yang, Shengping
    Bazzano, Alessandra N.
    Nigam, Somesh
    Hu, Gang
    DIABETES, 2020, 69
  • [47] THE ROLE OF NOVEL ANTI-DIABETIC AGENTS ON CARDIOVASCULAR RISK: FOCUS ON INCRETIN-BASED THERAPIES AND SGLT-2 INHIBITORS
    Rizzo, M. M. R. I.
    CARDIOLOGY, 2015, 132 : 107 - 107
  • [48] Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Classes of Glucose-Lowering Medications on Renal Outcome in Type 2 Diabetes
    Takeuchi, Masato
    Ogura, Masahito
    Minoura, Takaaki
    Inagaki, Nobuya
    Kawakami, Koji
    MAYO CLINIC PROCEEDINGS, 2020, 95 (02) : 265 - 273
  • [49] Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
    Powell, W. Ryan
    Christiansen, Cindy L.
    Miller, Donald R.
    DIABETES THERAPY, 2018, 9 (04) : 1431 - 1440
  • [50] Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
    W. Ryan Powell
    Cindy L. Christiansen
    Donald R. Miller
    Diabetes Therapy, 2018, 9 : 1431 - 1440
12345